BUSINESS
Zydus Life arm reports positive phase-3 trial results in rare liver disease, eyes USFDA nod in 2026
The Ahmedabad-based drugmaker plans to file for USFDA approval in the first quarter of 2026, targeting a market projected to reach $10.8 billion by 2026, growing at a CAGR of 36.3%.
BUSINESS
AHPI asks insurers to resume cashless services, ready to review its advisory
"In view of the discussions today, AHPI urged the insurers that they must immediately restore cashless services at its member hospitals, as the disruption is placing an unfair financial and emotional burden on patients," the association said in a statemen
BUSINESS
Delhi nursing home body alleges 'cartelization' of private insurers, seeks inflation-linked hospital tariffs
The Delhi Medical Association Nursing Home Forum (DMANHF) on Thursday filed a formal complaint with the Insurance Regulatory and Development Authority of India (IRDAI), alleging cartel-like behaviour by private insurers acting through the General Insurance Council (GIC).
BUSINESS
Oncology emerges as top revenue and profitability driver for India’s leading hospital chains
Once a niche segment, cancer care is now central to the strategic plans of Max Healthcare, Apollo Hospitals, and Fortis Healthcare, among others, driven by rising incidence, improved diagnostics, and high-complexity treatments that command premium pricing.
BUSINESS
AiMeD warns blanket GST rejig could hurt domestic MedTech, calls for balanced tax structure
The Association of Indian Medical Device Industry (AiMeD) said that while reducing GST to 5% on high-value equipment like electronics and implants could improve affordability and market reach, applying the same rate to low-margin consumables such as syringes, catheters, and IV sets would worsen the inverted duty structure—where inputs are taxed at 18% and outputs at 5% or 12% leading to margin compression and supply risks.
BUSINESS
GSK re-enters India’s oncology market with Jemperli and Zejula, unveils tiered pricing and patient support program
Bhushan Akshikar, Managing Director of GSK India, said the company is committed to making these therapies accessible through a tiered pricing strategy and a comprehensive patient support program branded Phoenix.
BUSINESS
Apollo Hospitals MD Suneeta Reddy sells 1.3% stake to cut debt
MD Suneeta Reddy has sold a 1.3 percent stake in the company through a block deal, raising approximately Rs 1,489 crore
BUSINESS
Abbott launches next gen CGM device FreeStyle Libre 2 Plus in India
The new sensor transmits glucose data directly to a smartphone without requiring manual scans, and can be worn for up to 15 days.
BUSINESS
Medical devices firm Biorad Medisys open to strategic investors to fund expansion and R&D push
Pune-based Biorad Medisys last year raised Rs 350 crore through optionally convertible debentures (OCDs) from Kotak Strategic Situations India Fund II for repaying previous debt, fund capex and expand footprint in both domestic and international markets.
BUSINESS
Fortis Healthcare expands UP footprint with 550-bed hospital in Lucknow
The facility, to be built near Gomti Nagar by the Ekana Group, will be positioned as a Centre of Excellence for tertiary care services.
BUSINESS
Advent-backed CDMO firm Cohance scouts for western API assets to meet demand and hedge against tariffs
Cohance already supplies API intermediates from India but sees strategic value in owning Western manufacturing capabilities.
BUSINESS
Accurius eyes $7 million fund raise for novel anti-cancer therapy, to leverage India for clinical trials & manufacturing
Srivatsan said the company is exploring trial sites in India, Australia, and the US, with a pre-IND (Investigational New Drug) meeting with the USFDA expected within six months of closing the round. Phase 1 trials will enroll 15–30 patients with lung-localized cancers, including non-small cell lung cancer and metastatic tumors.
BUSINESS
Amansa invests Rs 250 crore in Rubicon Research ahead of IPO
The deal involved the transfer of 5.16 million equity shares by General Atlantic Singapore RR Pte. Ltd to Amansa at Rs 484.47 a share
BUSINESS
Max Healthcare doubles down on hospital expansion, plans new facility in Gurugram
The company plans to add 1,500 beds by the end of the year, as part of aggressive expansion strategy to drive higher-margin growth
BUSINESS
Lilly launches Mounjaro KwikPen in India, matches vial pricing for diabetes and obesity
Each KwikPen contains four doses, designed for single-patient use, and is priced between Rs14,000 and Rs 27,500 per month depending on strength.
BUSINESS
Apollo Hospitals Q1FY26 net profit jumps 42% to Rs 433 crore
The company’s core healthcare services or hospital division contributed ₹2,935 crore in revenue, up 11%, with EBITDA at ₹718 crore.
BUSINESS
New rules, naming and shaming as cosmetics industry gets a regulatory makeover
The government has come out with more stringent regulations as there has been a proliferation of new players in the industry, which has lower entry barriers, is self-regulated and mostly relies on third-party contract manufacturers
BUSINESS
India’s weight-loss drug market hits Rs 606 crore; El Lilly's Mounjaro takes the lead
There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's Wegovy, which are both once-in-a-week injections
BUSINESS
Biocon gears up to ride weight-loss drug boom to script next growth chapter
Managing director & CEO Siddharth Mittal says is de-risking supply chain as Trump tariffs loom. 'We’re scenario-mapping but there’s a limit to how much we can do,' he tells Moneycontrol
BUSINESS
Biocon posts Rs 31 crore net profit in Q1FY26
Operating revenue grew 15% YoY to Rs 3,942 crore, with EBITDA rising 19% to Rs 829 crore.
BUSINESS
Eris Lifesciences eyes Novo Nordisk’s exit to expand human insulin play in India
Eris is preparing for a “day-one” launch of semaglutide in India once the patent expires in March 2026.
BUSINESS
SCHOTT expands India footprint with first local production of syringe and cartridge glass tubing
German glassmaker bets on GLP-1 boom and pharma self-reliance with new facility in Gujarat
BUSINESS
Trump's tariff threats: Indian Pharma is ready with a multi-pronged defence strategy
Indian drugmakers are responding with geographic diversification, supply-chain resilience and acquisition of US assets to brace for a potential disruption despite the current exemption
BUSINESS
Indian pharma dodges Trump’s additional 25% tariff for now
Exemption tied to national security probe buys time, but Section 232 investigation keeps sector on edge
